Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.

Literature DB >> 1555749

Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.

Abstract

The Human pancreatic carcinoma cell line KP-1N and its clone KP-1NL which has a high rate of liver metastasis were established. Ki-ras DNA point mutation on the codon 12 was found. The growth of KP-1N was stimulated by a physiological range of concentration (10(-11)-10(-10) M) of cholecystokinin and the increase was inhibited by the addition of a cholecystokinin receptor antagonist (CR 1505). Daily injections of CR 1505 (35 mg/kg) diminished the number of tumor colonies in the liver that were formed after an intrasplenic injection of the highly liver metastatic KP-1NL cells. These results suggest that cholecystokinin antagonists may be useful as growth inhibitors for some pancreatic cancer.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1992 PMID： 1555749 DOI： 10.1007/bf02775067

Source DB: PubMed Journal: Gastroenterol Jpn ISSN： 0435-1339

10 in total

1. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium.

Authors: J P Smith; S T Kramer; T E Solomon
Journal: Regul Pept Date: 1991-02-26

2. Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas.

Authors: C M Townsend; P Singh; J C Thompson
Journal: Gastroenterology Date: 1986-10 Impact factor: 22.682

3. Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas.

Authors: B R Douglas; R A Woutersen; J B Jansen; A J de Jong; L C Rovati; C B Lamers
Journal: Gastroenterology Date: 1989-02 Impact factor: 22.682

4. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.

Authors: M Niederau; C Niederau; G Strohmeyer; J H Grendell
Journal: Am J Physiol Date: 1989-01

5. Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3.

Authors: M L Frazier; S Pathak; Z W Wang; K Cleary; S E Singletary; M Olive; B Mackay; P A Steck; B Levin
Journal: Pancreas Date: 1990 Impact factor: 3.327

6. Differentiation features of human pancreatic tumor cells maintained in nude mice and in culture: immunocytochemical and ultrastructural studies.

Authors: E Hollande; V Trocheris de St-Front; P Louet-Hermitte; J Bara; J Péquignot; A Estival; F Clemente
Journal: Int J Cancer Date: 1984-08-15 Impact factor: 7.396

7. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma.

Authors: M Tada; M Omata; M Ohto
Journal: Gastroenterology Date: 1991-01 Impact factor: 22.682

8. Anticholecystokinin activities of loxiglumide.

Authors: I Setnikar; M Bani; R Cereda; R Chisté; F Makovec; M A Pacini; L Revel
Journal: Arzneimittelforschung Date: 1987-10

9. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors: K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal: Int J Cancer Date: 1989-06-15 Impact factor: 7.396

10. Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice.

Authors: Y Ikeda; M Ezaki; I Hayashi; D Yasuda; K Nakayama; A Kono
Journal: Jpn J Cancer Res Date: 1990-10